Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced CRC and KRAS G12D Inhibitor in Advanced ...

Impact of time to relapse (TTR) and metastasectomy (MTS) on survival in leiomyosarcoma (LMS): A CanSaRCC study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...

CStone Pharmaceuticals (CStone, HKEX: 2616),  an innovation-driven biopharmaceutical company focused on the research and ...

Incyte (Nasdaq:INCY) today announced that results from Phase 1 proof-of-concept studies of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, and INCB161734, a novel, selective and ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi ...

Incyte (INCY) announced the first clinical data evaluating its TGFbetaR2PD-1 bispecific antibody for patients with microsatellite stable, MSS, ...

In terms of safety, among participants receiving monotherapy and combination therapy, 19 (27.9%) and 26 (35.6%) reported treatment-related adverse events (TRAEs) of Grade 3 or higher, respectively.

Exploration of the evolving role of 18F-FDG PET/CT in evaluating extrahepatic cholangiocarcinoma lymph node metastasis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...

Golidocitinib combined with PD-1 antibodies achieved a 44.3% response rate in NSCLC patients post anti-PD-1 therapy progression. The combination therapy showed a complete response rate of 23.9% and a ...